This segment focuses on the research, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics is developing a pipeline of oral, small molecule drugs targeting unmet medical needs in endocrinology. Key R&D activities include preclinical studies, clinical trials (Phase 1, 2, and potentially 3), and regulatory submissions. The company utilizes advanced drug discovery techniques and collaborates with research institutions and clinical trial sites. The primary therapeutic areas include acromegaly, carcinoid syndrome, and congenital hyperinsulinism. The goal is to improve patient outcomes by providing effective and convenient oral treatments, addressing symptoms, and potentially slowing disease progression. Market positioning is based on being a leader in developing oral therapies for rare endocrine conditions, with a competitive advantage in its focus on unmet needs. Future opportunities include expanding the pipeline, seeking regulatory approvals, and commercializing approved products. Regulatory aspects involve FDA and EMA interactions. Partnerships include collaborations for drug development and commercialization, such as the partnership with Sanwa Kagaku Kenkyusho for Paltusotine in Japan.